

Supplementary Table 1 previous treatment lines per study subject

Patient	Treatment before nivolumab
ID 1	TACE, TARE, sorafenib
ID 2	RFA, TACE, sorafenib, capecitabine, GEMOX, doxorubicine, FOLFOX, sorafenib, regorafenib, cabozantinib, folfox
ID 3	TACE, sorafenib, resection, RFA
ID 4	GEMOX, doxorubicine, sorafenib, capecitabine
ID 5	TACE
ID 6	TACE, sorafenib
ID 7	TACE, GEMOX
ID 8	TACE, sorafenib, regorafenib
ID 9	GEMOX, sorafenib, regorafenib
ID 10	TARE
ID 11	None (no TKI due to recent variceal bleeding and persistence of red signs on gastroscopy)
ID 12	TACE, SBRT
ID 13	TACE, sorafenib
ID 14	TACE, sorafenib, TARE, TACE
ID 15	TACE (TKI contraindicated due to lower limb arterial disease)
ID 16	TARE 2x, TACE 2x
ID 17	Sorafenib
ID 18	Sorafenib, regorafenib
ID 19	Sorafenib
ID 20	SIRT(Y90), Sorafenib
ID 21	SIRT(Y90), Sorafenib
ID 22	Sorafenib, Regorafenib
ID 23	Sorafenib
ID 24	Sorafenib, Regorafenib
ID 25	Resection

ID 26	None (due to major cardiovascular and ischemic comorbidities)
ID 27	Sorafenib
ID 28	Resection, RFA
ID 29	SIRT (2x)
